BIRMINGHAM, Ala., Aug. 12 /PRNewswire/ -- Atherotech, Inc., developer of the VAP Cholesterol Test, has announced the addition of two new cardiometabolic tests as it continues to grow its cardiodiagnostic business.
The company has added the PLAC Test for identification of increased heart attack and stroke risk, and the Cystatin C test as an early, sensitive marker for chronic kidney disease. The tests expand Atherotech's cardiovascular disease and metabolic panels that complement the company's advanced lipid profile, the VAP (Vertical Auto Profile) Test.
"We're seeing increased demand and experiencing strong growth in our business," said Atherotech President and CEO Mike Mullen, "and the marketplace is responding positively to our offering. Look for Atherotech to continue adding to the value of our core VAP lipid test by giving physicians and cardiology practices a single source for multiple cardiovascular disease and metabolic test panels."
Atherotech is privately held and doesn't disclose specific figures, but Mullen said that he expects revenues for his company to increase more than 20 percent in 2009 compared to last year, with profits increasing as well. Mullen believes the VAP lipid test is the centerpiece for this growth.
"We're providing valuable and clinically relevant information at a low cost, which leads to accurate diagnosis, targeted treatment and positive outcomes. This is a positive development for all stakeholders within our current health care environment, including managed care payers, patients, doctors and other health care providers," explained Mullen.
Cardiometabolic and genetic tests already available from Atherotech include C-Reactive Protein (hsCRP), apoE genotype, NT-proBNP, homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D and insu
|SOURCE Atherotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved